Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

被引：2
|
作者：
Lin, Ningjing [1 ]
Sun, Xiuhua [2 ]
Zhou, Hui [3 ]
Zou, Liqun [4 ]
Zhou, Keshu [5 ]
Liu, Lihong [6 ]
Yang, Haiyan [7 ]
Hu, Kai [8 ]
Cai, Qingqing [9 ]
Liu, Yao [10 ]
Jin, Jie [11 ]
Zhang, Liling [12 ]
Li, Wenyu [13 ]
Guo, Ye [14 ]
Yang, Wei [15 ]
Luo, Feng [16 ]
Li, Yanyan [16 ]
Zhang, Mengqi [16 ]
Lu, Feinan [16 ]
Song, Yuqin [17 ]
Zhu, Jun [18 ]
机构：
[1] Beijing Canc Hosp, Dept Lymphat Oncol, Beijing, Peoples R China
[2] Dalian Med Univ, Hosp 2, Dalian, Peoples R China
[3] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[4] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[5] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Canc Hosp, Zhengzhou, Peoples R China
[6] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[7] Zhejiang Canc Hosp, Dept Lymphat Oncol, Hangzhou, Peoples R China
[8] Beijing Boren Hosp, Dept Adult Lymphoma, Beijing, Peoples R China
[9] Sun Yat Sen Univ, Canc Cente, Guangzhou, Peoples R China
[10] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China
[11] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[12] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China
[13] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[14] Shanghai East Hosp, Shanghai, Peoples R China
[15] China Med Univ, Dept Hematol, Shengjing Hosp, Shenyang, Peoples R China
[16] Overland Pharmaceut, Shanghai, Peoples R China
[17] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Lymphoma, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China
[18] Peking Univ, Canc Hosp, Beijing, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-173645
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Hamadani, Mehdi
    Chen, Lei
    Song, Yan
    Xu, Michael K.
    Liao, Laura
    Caimi, Paolo F.
    Carlo-Stella, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : E738 - E744
  • [42] Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study
    Caimi, Paolo F.
    Ai, Weiyun Z.
    Alderuccio, Juan Pablo
    Ardeshna, Kirit M.
    Hamadani, Mehdi
    Hess, Brian
    Kahl, Brad S.
    Radford, John
    Solh, Melhem
    Stathis, Anastasios
    Zinzani, Pier Luigi
    Wang, Ying
    Qin, Yajuan
    Wang, Luqiang
    Xu, Zhiying Cindy
    Carlo-Stella, Carmelo
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 1184 - 1193
  • [43] Sustained disease control and correlative analyses in tisagenlecleucel treated relapsed/refractory diffuse large B-Cell lymphoma patients (r/r DLBCL)
    Borchmann, P.
    Bachanova, V.
    Westin, J.
    Tam, C.
    Jaeger, U.
    McGuirk, J.
    Holte, H.
    Waller, E.
    Jaglowski, S.
    Bishop, M.
    Andreadis, C.
    Foley, S. R.
    Fleury, I.
    Teshima, T.
    Mielke, S.
    Salles, G.
    Ho, J.
    Izutsu, K.
    Maziarz, R.
    van Besein, K.
    Kersten, M. J.
    Wagner-Johnston, N.
    Kato, K.
    Corradini, P.
    Han, X.
    Agoulnik, S.
    Chu, J.
    Eldjerou, L.
    Pacaud, L.
    Schuster, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 238 - 238
  • [44] Efficacy and safety of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
    Habermann, T.
    Lossos, I.
    Justice, G.
    Tuscano, J.
    Cole, C.
    Vose, J.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Wiernik, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 150 - 150
  • [45] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
    Mueller, Karen Thudium
    Grupp, Stephan A.
    Maude, Shannon L.
    Levine, John E.
    Pulsipher, Michael
    Boyer, Michael W.
    August, Keith Jason
    Myers, Gary Douglas
    Awasthi, Rakesh
    Waldron, Edward K.
    Bubuteishvili-Pacaud, Lida
    Taran, Tanya
    Cota, Mariana
    Tam, Constantine Si Lun
    Jager, Ulrich
    Foley, Ronan
    Borchmann, Peter
    Schuster, Stephen J.
    Waller, Edmund K.
    Laetsch, Theodore Willis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Efficacy, Safety, and Patient-Reported Outcomes (PROs) of Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A Systematic Literature Review (SLR)
    Ma, Qiufei
    Xu, Yingxin
    Srivastava, Rajni
    Kaushik, Namita
    Kaur, Mandeep
    Meng, Yang
    Quek, Ruben G. W.
    Mohamed, Hesham
    Ambati, Srikanth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S396 - S396
  • [47] Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study
    Cavallo, Federica
    Follows, George A.
    Goy, Andre
    Vermaat, Joost
    Casasnovas, Rene-Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee M.
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian T.
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael W.
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros P.
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel A.
    Kalakonda, Nagesh
    BLOOD, 2019, 134
  • [48] CHARACTERIZATION AND MANAGEMENT OF CUTANEOUS REACTIONS IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH LONCASTUXIMAB TESIRINE IN THE LOTIS-2 TRIAL
    Pruett, Julie
    Zellner, Katie
    Kahl, Brad
    Ungar, David
    Wang, Luqiang
    Hamadani, Mehdi
    ONCOLOGY NURSING FORUM, 2022, 49 (02) : E59 - E59
  • [49] In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
    Caimi, Paolo F.
    Hamadani, Mehdi
    Carlo-Stella, Carmelo
    Nickaeen, Masoud
    Jordie, Eric
    Utsey, Kiersten
    Knab, Tim
    Zammarchi, Francesca
    Cucchi, Danilo
    Pantano, Serafino
    Havenith, Karin
    Wang, Ying
    Boni, Joseph
    EJHAEM, 2024, 5 (01): : 76 - 83
  • [50] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
12345